OPKO Health (NASDAQ:OPK) Issues Earnings Results

OPKO Health (NASDAQ:OPK) announced its quarterly earnings results on Monday. The biotechnology company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.07, FiscalAI reports. The company had revenue of $163.58 million for the quarter, compared to analyst estimates of $131.23 million. OPKO Health had a negative net margin of 36.63% and a negative return on equity of 16.78%. OPKO Health’s quarterly revenue was up 4.3% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.19) EPS.

Here are the key takeaways from OPKO Health’s conference call:

• OPKO significantly improved profitability in Q2, with consolidated revenue rising to $163.6 million, operating loss narrowing to $7 million from $60 million, and net loss improving to $8.4 million from $148.4 million.
• Management raised full-year 2026 revenue guidance to $560 million-$585 million and reduced total cost and expense guidance to $710 million-$740 million, while maintaining its expectation that BioReference will reach breakeven or operating profitability this year.
• The pipeline continues to advance, including five ModeX programs in clinical development, an expected first-in-human trial for the in vivo CAR-T program by late 2026 or early 2027, and the initiation of a Phase I/IIa trial for the GLP-1/glucagon candidate OPKO-88006 in MASH.
• OPKO ended the quarter with more than $300 million in cash and restricted cash and repurchased 9.7 million shares for approximately $13 million, with another $94 million authorized for buybacks.
• BioReference’s 4Kscore growth and broader primary-care expansion remain dependent on Medicare reimbursement changes that have not yet been approved, with management now expecting the larger opportunity to contribute mainly from 2027 onward; full-year services guidance was also reduced slightly.

OPKO Health Trading Up 1.6%

Shares of NASDAQ:OPK opened at $1.24 on Tuesday. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.17 and a current ratio of 3.61. The stock’s 50-day moving average is $1.37 and its 200-day moving average is $1.26. The company has a market cap of $936.31 million, a P/E ratio of -4.59 and a beta of 1.48. OPKO Health has a 52-week low of $0.98 and a 52-week high of $1.61.

Analysts Set New Price Targets

OPK has been the topic of several analyst reports. Weiss Ratings raised shares of OPKO Health from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, May 18th. Wall Street Zen raised OPKO Health from a “sell” rating to a “hold” rating in a research report on Saturday, June 6th. Finally, Barrington Research downgraded OPKO Health from an “outperform” rating to a “market perform” rating in a research note on Wednesday, April 29th. Four analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Reduce” and a consensus target price of $1.55.

Key Headlines Impacting OPKO Health

Here are the key news stories impacting OPKO Health this week:

• Positive Sentiment: OPKO reported a second-quarter loss of $0.01 per share, substantially better than the $0.08 loss analysts expected and the $0.19 loss recorded a year earlier. Revenue increased 4.3% year over year to $163.58 million, exceeding the $131.23 million consensus estimate. OPKO Health Reports Second Quarter 2026 Business Highlights and Financial Results
• Positive Sentiment: Management raised its 2026 revenue guidance to $560 million-$585 million, above the approximately $536.4 million analyst estimate. The outlook signals improved expectations for OPKO’s commercial business and could support investor confidence. OPKO 2026 Revenue Guidance and MDX3001 Clinical Plans
• Positive Sentiment: OPKO continues to advance its pipeline: ModeX presented data on multispecific antibody programs designed to target in-vivo CAR-T cell therapies, with Phase 1 studies planned for late 2026 or early 2027. The company also expects to begin clinical development of MDX3001 by the end of 2026 or early 2027, providing additional potential catalysts. OPKO Health Second-Quarter Business Highlights
• Neutral Sentiment: Third-quarter revenue guidance of $131 million-$142 million brackets the $134.8 million consensus estimate. This is generally in line with expectations but offers less of an upside surprise than the full-year outlook.
• Negative Sentiment: Despite the quarterly beat, OPKO remains loss-making, with a negative net margin of 36.63% and negative return on equity. Sustained profitability and execution of its clinical pipeline remain important risks for the stock.

Institutional Trading of OPKO Health

Hedge funds have recently added to or reduced their stakes in the business. Virtu Financial LLC bought a new position in OPKO Health in the 4th quarter worth approximately $145,000. EP Wealth Advisors LLC bought a new stake in shares of OPKO Health in the fourth quarter valued at approximately $37,000. XTX Topco Ltd acquired a new stake in shares of OPKO Health in the fourth quarter worth $432,000. Zacks Investment Management acquired a new stake in shares of OPKO Health in the fourth quarter worth $27,000. Finally, Quadrature Capital Ltd acquired a new stake in shares of OPKO Health in the fourth quarter worth $116,000. Institutional investors own 64.63% of the company’s stock.

About OPKO Health

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.